Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with gene therapy Elevidys (delandistrogene ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. UBS upgraded ...

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

US tech giants rebounded collectively on Monday. Apple rose 1%, Microsoft rose 0.88%, Amazon rose 1.89%, NVIDIA rose 1.92%, Alphabet (Google-A) rose 1.20%, Tesla rose 1.17%, Meta rose 2.9%, and ...